CD86 and rheumatoid arthritis: However, the recently completed ACCLAIM clinical trial with abatacept, blocking CD80-CD86 co-stimulation and approved for rheumatoid arthritis and juvenile idiopathic arthritis, failed in multiple sclerosis (Khoury et al., 2017).